The Sanofi Dengvaxia controversy began when 800,000 Filipino schoolchildren were vaccinated before the manufacturer revealed the vaccine could worsen dengue in previously unexposed recipients — a case study in vaccine safety failures.
Sanofi is one of the four major pharmaceutical companies ("the big four") that sell vaccines on the CDC's childhood schedule. It is the company with which Stanley Plotkin had the most consistent documented financial relationship.
Role in Vaccine Policy
One of the "big four" vaccine manufacturers alongside Merck, Pfizer, and GSK
Key Findings
Stanley Plotkin testified there was likely no year since 1990 in which he received no payment or remuneration from Sanofi. When asked how much he had received, he responded: "I have no idea. I'm sure it's a sizable amount of money."
Tina Tan: consultant; committee member; research funding recipient; recipient of worldwide paid trips; speakers' bureau — all Sanofi
Key People (pharma ties)
Stanley Plotkin — consulting; ongoing payments since at least 1990
Tina Tan — consultant; committee member; advisory roles; research funding; paid international travel; speakers' bureau
What happened with Sanofi's Dengvaxia vaccine in the Philippines?
Sanofi's Dengvaxia is the only routine vaccine licensed with a true placebo-controlled trial and 5-year follow-up. That trial found children under 6 and seronegative children had significantly increased risk of severe harm and death from the vaccine — via antibody-dependent enhancement (ADE). Approximately 800,000 Filipino schoolchildren were vaccinated before these risks were fully disclosed. The vaccine is now restricted to older, seropositive children only.
How much has Stanley Plotkin received from Sanofi?
Plotkin testified there was likely no year since 1990 in which he received no payment or remuneration from Sanofi. When asked the total amount, he responded: "I have no idea. I'm sure it's a sizable amount of money." Sanofi is the pharma company with which Plotkin has the most consistent documented financial relationship spanning over three decades.
Which Sanofi vaccines are on the CDC childhood schedule?
Sanofi manufactures Daptacel (DTaP), ActHIB (Hib), IPOL (polio), Pentacel (combination DTaP+Hib+IPV), Quadracel (DTaP+IPV booster), Adacel (Tdap), Menactra (MenACWY), MenQuadfi (MenACWY), and multiple flu vaccines. None were tested against an inert placebo. IPOL was licensed with 3-day safety monitoring, no control group, and deaths occurred in temporal association.
What are Tina Tan's financial ties to Sanofi?
Tina Tan serves as a consultant, committee member, research funding recipient, and speakers' bureau participant for Sanofi. She has also received worldwide paid trips from Sanofi. Despite these extensive financial relationships, she is regularly quoted in media as an impartial scientist on vaccine safety topics.
What did the Dengvaxia controversy teach about vaccine safety testing?
Dengvaxia is the only routine vaccine that had a placebo-controlled trial with 5 years of follow-up — and that trial revealed serious harms that would never have been detected in a standard short-window trial. Aaron Siri argues this demonstrates what proper trial design can find: if similar long-term placebo-controlled trials were required for all childhood vaccines, dangerous products could have been identified before reaching millions of children.
This is the plain-HTML rendering of organizations/Sanofi.md, served for search
engines, AI crawlers, and accessibility tools. The interactive 3D version
of this wiki lives at vaccine-safety.org.